Industry News

Cohera Medical Secures US Patent for its Pressure Sensitive Adhesive

Published on 2014-12-03. Author :

Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,895,052, titled “Biodegradable Compositions Having Pressure Sensitive Adhesive Properties.”

The patent relates to a novel adhesive designed for surgical mesh or matrix fixation in clinical applications such as hernia repair. Use of the adhesive could replace the often painful and complicated mechanical fixation methods currently used in surgical mesh placement. The adhesives covered by the patent are high-strength, completely synthetic and resorbable. A key unique feature is that the adhesive is designed to maintain a solid state at room temperature, and then become sticky when exposed to moisture and heat in tissue, allowing it to be manipulated and placed laparoscopically. The patent covers variations of this adhesive that allows for multiple products with varying strengths and cure properties, thereby enabling the development of products for additional clinical applications and surgical methods.

“The unique chemistry of this synthetic pressure-sensitive adhesive is a breakthrough in the field of medical glues,” said Dottie Clower, Ph.D., Chief Scientific Officer of Cohera Medical. “This patent represents a significant advance in the state of the art, and is the culmination of a significant research effort by the company.”

“We are excited to add this patent to our growing intellectual property portfolio, which enhances our leadership position in internal surgical adhesives,” said Patrick Daly, President and Chief Executive Officer of Cohera Medical. “This patent protects novel technology that could change the landscape in the surgical placement of meshes and matrices to the benefit of patients worldwide.”

About Cohera Medical
Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives and sealants. Cohera Medical’s products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company’s lead product, TissuGlu® Surgical Adhesive, is indicated in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty. TissuGlu® is currently approved for sale in the EU and is being utilized to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty (tummy tuck), mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. The Company’s second product, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, is currently under the CE Mark approval process. TissuGlu and Sylys are the first in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. Outside of the EU, TissuGlu and the other Cohera Medical products are currently indicated for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market.

Forward Looking Statements
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.

Source: Cohera Medical

Omya Calcium Carbonates
Naphthenic Oils For Better Adhesion
Channel Alerts

Receive weekly digests on hot topics

Back to Top